Recruiting
Phase 3

AZD6234

Sponsor:

AstraZeneca

Code:

NCT07784725

Conditions

Obesity or Overweight

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

AZD6234

Placebo

Study Details

Brief summary:

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

Conditions

Obesity or Overweight

Study ID

NCT07784725

Start date

Aug 19, 2026

Status verified date

Aug, 2026

Completion date

May 21, 2029

Anticipated

Primary completion date

Aug 11, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Males \& females (inclusive of all gender identities) age ≥18 years
  • BMI ≥30 kg/m2 OR BMI ≥27 kg/m2 with at least one of the following weight related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, heart failure, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, osteoarthritis of the knee, or stress urinary incontinence
  • Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation
  • History of at least one self-reported unsuccessful attempt to lose body weight in their lifetime

Exclusion Criteria:

  • Obesity primarily caused by other endocrine disorders
  • History of Type 1 or Type 2 Diabetes Mellitus, HbA1c ≥6.5% (48 mmol/mol), and/or treatment with glucose-lowering agent(s) within 3 months prior to Screening
  • Significant hepatobiliary disease and/or any of the following results at Screening:

  • ALT ≥ 3.0 × ULN
  • AST ≥ 3.0 × ULN
  • TBL > 1.5 × ULN (except for cases of known Gilbert's Syndrome)
  • Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation.

Study Design

Enrollment

2500 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: AZD6234 Dose 1

AZD6234 Dose 1

experimental: AZD6234 Dose 2

AZD6234 Dose 2

placebo comparator: Placebo

Matching placebo

Interventions

AZD6234

IMP injected subcutaneously, once a week. Unit dose strength as per CSP.

Placebo

Placebo matching IMP dose injected subcutaneously, once a week.

Primary outcome measure

  • Percent change in body weight from baseline at 68 weeks of treatment [ Time Frame: 68 weeks ]

Central Contacts and Locations

Central contacts

AstraZeneca Clinical Study Information Center

1-877-240-9479information.center@astrazeneca.com

Locations

Research Site

Recruiting

Mississauga, Ontario, Canada, L5K2L3

Research Site

Recruiting

Stouffville, Ontario, Canada, L4A1H2

More Information

Sponsor

AstraZeneca

Last update posted

Aug 25, 2026

Last verified

Aug, 2026

Keywords

  • Obesity
  • Overweight
  • AZD6234

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by AstraZeneca on 2026-08-25.